RBN-2397 |
| Katalog-Nr.GC39504 |
RBN-2397 ist ein potenter, speziesÜbergreifender und oral aktiver kompetitiver NAD+-Inhibitor von PARP7 (IC50<3 nM). RBN-2397 bindet selektiv an PARP7 (Kd =0,001 μM) und stellt die IFN-Signalgebung wieder her. RBN-2397 hat das Potenzial fÜr die Untersuchung von fortgeschrittenen oder metastasierten soliden Tumoren.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2381037-82-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
RBN-2397 is a potent, accross species and orally active NAD+ competitive inhibitor of PARP7 (IC50<3 nM). RBN-2397 selectively binds to PARP7 (Kd=0.001 μM) and restores interferon (Type I) signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors[1][2].
[1]. RBN-2397-Inhibiting PARP7, a Key monoPARP Cancer Dependency [2]. Melissa Vasbinder, et al. RBN-2397: A First-in-Class PARP7 Inhibitor Targetinga Newly Discovered Cancer Vulnerability in Stress-Signaling Pathways.
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *